WEBULL

Givaudan (SWX:GIVN) Following Weaker Half Year Results Is Its Valuation Still Compelling

Simply Wall St · 3d ago

Givaudan (SWX:GIVN) is back in focus after half year 2026 results showed sales of CHF 3,799 million and net income of CHF 475 million, both below the prior year period.

See our latest analysis for Givaudan.

Givaudan's share price has slipped in recent weeks, with a 7 day share price return of down 5.38% and a 30 day share price return of down 5.16%. However, the 90 day share price return of 14.52% and 3 year total shareholder return of 16.50% point to momentum that has built over a longer horizon, despite a 1 year total shareholder return of down 6.05% and a 5 year total shareholder return of down 21.36%.

If earnings volatility has you reassessing your watchlist, this can be a good moment to broaden your search with 108 top founder-led companies

For Givaudan, weaker half-year earnings and a recent pullback could either hint at a real reset in the business or reflect cooler sentiment after a stronger 90-day run. How does the current valuation compare in that context?

Most Popular Narrative: 7.2% Undervalued

Givaudan's most followed narrative points to a fair value of CHF3,468 per share, compared with the last close at CHF3,218. That gap is built on specific growth and margin assumptions rather than sentiment alone.

The company continues to outpace industry peers, in part due to its innovation pipeline: launches of sustainable, natural ingredients (e.g., FDA-approved color solutions, algae-derived beauty actives) directly align with consumer shifts toward health, wellness, and clean label products, supporting both top-line growth and potential margin expansion.

Read the complete narrative.

Want to see what keeps this valuation model ticking despite slower profit growth than the wider market? The narrative leans heavily on steady revenue expansion, firmer margins over time and a premium earnings multiple that still edges down from today. The crucial link between those three drivers sits inside the full narrative.

Result: Fair Value of CHF3,468 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, Givaudan's story can change quickly if input cost pressures persist or if antitrust investigations lead to sizeable fines that dent margins and cash flow.

Find out about the key risks to this Givaudan narrative.

Next Steps

Mixed signals around Givaudan can create confusion, so use that to your advantage and move quickly to examine the full picture for yourself with 3 key rewards and 1 important warning sign

Looking for more investment ideas beyond Givaudan?

If Givaudan has sharpened your focus, do not stop here. Fresh opportunities often sit just outside your current watchlist, waiting for a closer look.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.